0001104659-23-123816.txt : 20231206 0001104659-23-123816.hdr.sgml : 20231206 20231206074618 ACCESSION NUMBER: 0001104659-23-123816 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20231206 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20231206 DATE AS OF CHANGE: 20231206 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Century Therapeutics, Inc. CENTRAL INDEX KEY: 0001850119 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 842040295 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-40498 FILM NUMBER: 231468437 BUSINESS ADDRESS: STREET 1: 25 N 38TH STREET, 11TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19104 BUSINESS PHONE: 215-981-4000 MAIL ADDRESS: STREET 1: 25 N 38TH STREET, 11TH FLOOR CITY: PHILADELPHIA STATE: PA ZIP: 19104 8-K 1 tm2332239d1_8k.htm FORM 8-K
false 0001850119 0001850119 2023-12-06 2023-12-06 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, DC 20549

 

 

 

FORM 8-K

 

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): December 6, 2023

 

 

 

Century Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-40498   84-2040295
(State or other jurisdiction of
incorporation or organization)		   (Commission File Number)   (I.R.S. Employer
Identification No.)

 

25 North 38th Street, 11th Floor

Philadelphia, Pennsylvania

  19104
(Address of principal executive offices)   (Zip Code)

 

Registrant’s telephone number, including area code: (267) 817-5790

 

Not Applicable

(Former name or former address, if changed since last report)

 

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

 

¨ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of Each Class   Trading Symbol   Name of Exchange on Which Registered
Common Stock, par value $0.0001 per share   IPSC   Nasdaq Global Select Market

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company x

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

 

 

 

 

 

Item 8.01 Other Events

 

On December 6, 2023, Century Therapeutics, Inc. (the “Company”) issued a press release announcing the Company has been notified by the U.S. Food and Drug Administration that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101 in patients with moderate to severe systemic lupus erythematosus who have failed at least two standard immunosuppressive therapies. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

 

Item 9.01 Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit
No.		   Document
99.1   Press Release of Century Therapeutics, Inc., dated December 6, 2023
     
104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  CENTURY THERAPEUTICS, INC.
     
  By: /s/ Brent Pfeiffenberger, Pharm.D.
  Name: Brent Pfeiffenberger, Pharm.D.
  Title: President and Chief Executive Officer

 

Date: December 6, 2023

 

 

 

 EX-99.1 2 tm2332239d1_ex99-1.htm EXHIBIT 99.1

 

Exhibit 99.1 

 

 

 

Century Therapeutics Receives FDA Clearance of IND Application for CNTY-101 in Systemic Lupus Erythematosus

 

– Represents second IND clearance for CNTY-101, the Company’s lead iPSC-derived CD19-targeted CAR NK cell product candidate, and first in an autoimmune and inflammatory disease indication –

 

– Company plans to initiate the Phase 1 clinical trial in the first half of 2024; initial data expected by year-end 2024 –

 

– CNTY-101 is the first cell therapy product candidate engineered with six precision gene edits including a CD19-CAR, Allo-Evasion™ technology, IL-15 cytokine support and a safety switch –

 

PHILADELPHIA, December [X], 2023 – Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology and autoimmune and inflammatory disease, today announced that the Company has been notified by the U.S. Food and Drug Administration (FDA) that the Company’s Phase 1 clinical trial may proceed to assess CNTY-101 in patients with moderate to severe systemic lupus erythematosus (SLE) who have failed at least two standard immunosuppressive therapies. This represents the first Investigational New Drug (IND) application clearance for an autoimmune and inflammatory disease indication for CNTY-101, and is built on the emerging data and experience gained from administering multiple cycles of CNTY-101, with and without lymphodepletion, under the open IND for CNTY-101 in relapsed/refractory B-cell malignancies.

 

Despite recent advances, therapies for SLE have failed to make a significant impact on morbidity, and induction of remission remains rare, while treatment toxicity and disease flares are common. B-cell-directed autologous CAR T cell therapies have provided new hope for durable remissions through an “immune reset”. However, some of the challenges encountered with auto-CAR-T in oncology related to product availability, toxicities, and potential long-term risks could hamper their wide-spread adoption in non-oncology indications. Century is pursuing an alternative approach with CNTY-101, an allogeneic, off-the-shelf iPSC-derived NK cell product candidate. CNTY-101 contains 6 genetic edits at defined loci, engineered via homology directed repair using CRISPR. These include three Allo-EvasionTM edits, secreted IL-15, a CD19 CAR, and a safety switch allowing for cell removal if required. As a homogenous NK cell candidate derived from a single iPSC clone, CNTY-101 has been designed with uniquely engineered features which Century believes may provide multiple potential treatment advantages. These potential advantages include availability of a consistent off-the-shelf frozen product, an improved tolerability profile, ability to be re-dosed without lymphodepletion while avoiding allo-rejection of the product, and a product design that may enable the elimination of B cells to effect a decline in auto-antibodies without prolonged B cell aplasia.

 

“Today marks an important milestone in Century’s evolution as a company. We believe the unique profile of CNTY-101, which incorporates multiple precision edits including our Allo-EvasionTM technology, positions it as an off-the-shelf allogeneic treatment option that could meaningfully improve outcomes for patients with SLE for whom existing therapies fall short,” said Brent Pfeiffenberger, Pharm.D., Chief Executive Officer of Century Therapeutics. “The expansion of the CNTY-101 program into SLE represents a significant achievement for the Company, and, importantly, serves as a testament to the unwavering dedication of our team as we continue to execute on our mission to advance differentiated and potentially curative cell therapies to patients with cancer and autoimmune and inflammatory diseases.”

 

 

 

 

 

 

The multi-center Phase 1 clinical trial is designed to assess the safety, tolerability, pharmacokinetics, and clinical response of CNTY-101 in patients with moderate to severe SLE who have failed at least two standard immunosuppressive therapies. The trial will evaluate one to two cycles of 3 weekly doses of CNTY-101, with lymphodepletion only included prior to the first CNTY-101 infusion. The Company plans to initiate the trial in the first half of 2024, with initial data expected by the end of 2024.

 

About Allo-Evasion™

 

Century’s proprietary Allo-Evasion™ technology is used to engineer cell therapy product candidates with the potential to evade identification by the host immune system so they can be dosed multiple times without rejection, enabling increased persistence of the cells during the treatment period and potentially leading to deeper and more durable responses. More specifically, Allo-Evasion™ 1.0 technology incorporates three gene edits designed to avoid recognition by patient/host CD8+ T cells, CD4+ T cells and NK cells. Knockout of beta-2-microglobulin or β2m, designed to prevent CD8+ T cell recognition, knock-out of the Class II Major Histocompatibility Complex Transactivator, or CIITA, designed to prevent CD4+ T cell recognition, and knock-in of the HLA-E gene, designed to enable higher expression of the HLA-E protein to prevent killing of CNTY-101 cells by host NK cells. Allo-Evasion™ technology may allow the implementation of more flexible and effective repeat dosing protocols for off-the-shelf product candidates.

 

About CNTY-101

 

CNTY-101 is an investigational off-the-shelf immunotherapy product candidate that utilizes iPSC-derived natural killer (NK) cells with a CD19-directed chimeric antigen receptor (CAR) and includes Century’s core Allo-Evasion™ edits designed to overcome the three major pathways of host versus graft rejection - CD8+ T cells, CD4+ T cells and NK cells. In addition, the product candidate is engineered to express IL-15 to provide homeostatic cytokine support, which has been shown pre-clinically to improve functionality and persistence. Further, to potentially improve safety, the iNK cells were engineered with an EGFR safety switch, and proof-of-concept studies have demonstrated that the cells can be quickly eliminated by the administration of cetuximab, an antibody against EGFR approved by the U.S. Food and Drug Administration for certain cancers. Century is currently assessing CNTY-101 in patients with relapsed or refractory CD19-positive B-cell lymphomas in its Phase 1 ELiPSE-1 clinical trial and intends to initiate its second Phase 1 clinical trial assessing CNTY-101 in patients with moderate to severe systemic lupus erythematosus.

 

About Century Therapeutics

 

Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer and autoimmune and inflammatory diseases that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived cell product candidates are designed to specifically target hematologic and solid tumor cancers, with a broadening application to autoimmune and inflammatory diseases. We are leveraging our expertise in cellular reprogramming, genetic engineering, and manufacturing to develop therapies with the potential to overcome many of the challenges inherent to cell therapy and provide a significant advantage over existing cell therapy technologies. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provide an unparalleled opportunity to advance the course of cancer and autoimmune and inflammatory disease care. For more information on Century Therapeutics please visit www.centurytx.com.

 

 

 

 

 

 

Century Therapeutics Forward-Looking Statement

 

This press release contains forward-looking statements within the meaning of, and made pursuant to the safe harbor provisions of, The Private Securities Litigation Reform Act of 1995. All statements contained in this press release, other than statements of historical facts or statements that relate to present facts or current conditions, including but not limited to, statements regarding our clinical development plans and timelines, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance, or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “should,” “expect,” “plan,” “aim,” “seek,” “anticipate,” “could,” “intend,” “target,” “project,” “contemplate,” “believe,” “estimate,” “predict,” “forecast,” “potential” or “continue” or the negative of these terms or other similar expressions. The forward-looking statements in this press release are only predictions. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our business, financial condition, and results of operations. These forward-looking statements speak only as of the date of this press release and are subject to a number of risks, uncertainties and assumptions, some of which cannot be predicted or quantified and some of which are beyond our control, including, among others: our ability to successfully advance our current and future product candidates through development activities, preclinical studies, and clinical trials; the timing of and our ability to initiate and successfully enroll the Phase 1 SLE trial, our dependence on the success of our lead product candidate, CNTY-101; uncertainties inherent in the results of preliminary data, pre-clinical studies and earlier-stage clinical trials being predictive of the results of early or later-stage clinical trials; our ability to obtain FDA clearance of our future IND submissions and commence clinical trials on expected timelines, or at all; our reliance on the maintenance of certain key collaborative relationships for the manufacturing and development of our product candidates; the timing, scope and likelihood of regulatory filings and approvals, including final regulatory approval of our product candidates; the impact of geopolitical issues, banking instability and inflation on our business and operations, supply chain and labor force; the performance of third parties in connection with the development of our product candidates, including third parties conducting our clinical trials as well as third-party suppliers and manufacturers; our ability to successfully commercialize our product candidates and develop sales and marketing capabilities, if our product candidates are approved; our ability to recruit and maintain key members of management and our ability to maintain and successfully enforce adequate intellectual property protection. These and other risks and uncertainties are described more fully in the “Risk Factors” section of our most recent filings with the Securities and Exchange Commission and available at www.sec.gov. You should not rely on these forward-looking statements as predictions of future events. The events and circumstances reflected in our forward-looking statements may not be achieved or occur, and actual results could differ materially from those projected in the forward-looking statements. Moreover, we operate in a dynamic industry and economy. New risk factors and uncertainties may emerge from time to time, and it is not possible for management to predict all risk factors and uncertainties that we may face. Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained herein, whether as a result of any new information, future events, changed circumstances or otherwise.

 

For More Information:

Investors/Media: Melissa Forst/Maghan Meyers – century@argotpartners.com

 

 

 

 EX-101.SCH 3 ipsc-20231206.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 ipsc-20231206_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 ipsc-20231206_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm2332239d1_ex99-1img11.jpg GRAPHIC begin 644 tm2332239d1_ex99-1img11.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.3
Cover
Dec. 06, 2023
Cover [Abstract]  
Document Type 8-K
Amendment Flag false
Document Period End Date Dec. 06, 2023
Entity File Number 001-40498
Entity Registrant Name Century Therapeutics, Inc.
Entity Central Index Key 0001850119
Entity Tax Identification Number 84-2040295
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 25 North 38th Street
Entity Address, Address Line Two 11th Floor
Entity Address, City or Town Philadelphia
Entity Address, State or Province PA
Entity Address, Postal Zip Code 19104
City Area Code 267
Local Phone Number 817-5790
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001 per share
Trading Symbol IPSC
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Elected Not To Use the Extended Transition Period false
XML 8 tm2332239d1_8k_htm.xml IDEA: XBRL DOCUMENT 0001850119 2023-12-06 2023-12-06 iso4217:USD shares iso4217:USD shares false 0001850119 8-K 2023-12-06 Century Therapeutics, Inc. DE 001-40498 84-2040295 25 North 38th Street 11th Floor Philadelphia PA 19104 267 817-5790 false false false false Common Stock, par value $0.0001 per share IPSC NASDAQ true false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.3 html 1 24 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://centurytx.com/role/Cover Cover Cover 1 false false All Reports Book All Reports ipsc-20231206.xsd ipsc-20231206_lab.xml ipsc-20231206_pre.xml tm2332239d1_8k.htm http://xbrl.sec.gov/dei/2023 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm2332239d1_8k.htm": { "nsprefix": "IPSC", "nsuri": "http://centurytx.com/20231206", "dts": { "schema": { "local": [ "ipsc-20231206.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "ipsc-20231206_lab.xml" ] }, "presentationLink": { "local": [ "ipsc-20231206_pre.xml" ] }, "inline": { "local": [ "tm2332239d1_8k.htm" ] } }, "keyStandard": 24, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 24 }, "report": { "R1": { "role": "http://centurytx.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2023-12-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332239d1_8k.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2023-12-06", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm2332239d1_8k.htm", "first": true, "unique": true } } }, "tag": { "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://centurytx.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 15 0001104659-23-123816-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-23-123816-xbrl.zip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end